BRPI0412519A - partìculas tipo vìrus da influenza funcional (vlps) - Google Patents

partìculas tipo vìrus da influenza funcional (vlps)

Info

Publication number
BRPI0412519A
BRPI0412519A BRPI0412519-3A BRPI0412519A BRPI0412519A BR PI0412519 A BRPI0412519 A BR PI0412519A BR PI0412519 A BRPI0412519 A BR PI0412519A BR PI0412519 A BRPI0412519 A BR PI0412519A
Authority
BR
Brazil
Prior art keywords
influenza virus
influenza
particles
vaccine
recombinant
Prior art date
Application number
BRPI0412519-3A
Other languages
English (en)
Inventor
Robin A Robinson
Peter M Pushko
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BRPI0412519A publication Critical patent/BRPI0412519A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

"PARTìCULAS TIPO VìRUS DE INFLUENZA FUNCIONAL". Proteínas do vírus da influenza recombinante, incluindo capsómeros da influenza, partículas subvirais, partículas como vírus (VLP), complexos VLP, e/ou quaisquer porções destes, são fornecidos como uma vacina para viroses da influenza. A invenção é baseada na combinação de duas tecnologias de vacina: (1) tecnologia de vacina recombinante intrinsicamente segura, e (2) macromoléculas de proteína auto-agrupadas, altamente imunogênicas, embebidas em membranas de plasma e compreendidas de cópias múltiplas de proteínas estruturais de vírus da influenza exibindo epítopos neutralizantes em conformações nativas. Mais especificamente, esta invenção refere-se ao planejamento e produção de partículas como vírus das influenza recombinantes homotípicas e heterotípicas funcionais (VLPs) compreendidas de proteínas estruturais recombinantes de vírus da influenza humana tipo A/Sydney/5/94 (H3N2) e/ou vírus da influenza aviária tipo A/Hong Kong/1073199 (H9N2) em células de inseto infectadas por baculovírus e sua aplicação como uma vacina na prevenção de infecções de influenza e como um reagente de laboratório para estudos estruturais de vírus e diagnósticos clínicos.
BRPI0412519-3A 2003-07-11 2004-07-09 partìculas tipo vìrus da influenza funcional (vlps) BRPI0412519A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/617,569 US8592197B2 (en) 2003-07-11 2003-07-11 Functional influenza virus-like particles (VLPs)
PCT/US2004/022001 WO2005020889A2 (en) 2003-07-11 2004-07-09 Functional influenza virus-like particles (vlps)

Publications (1)

Publication Number Publication Date
BRPI0412519A true BRPI0412519A (pt) 2006-09-19

Family

ID=33565000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412519-3A BRPI0412519A (pt) 2003-07-11 2004-07-09 partìculas tipo vìrus da influenza funcional (vlps)

Country Status (20)

Country Link
US (5) US8592197B2 (pt)
EP (2) EP2343084B1 (pt)
JP (5) JP2007529997A (pt)
KR (1) KR101153929B1 (pt)
CN (3) CN103157103A (pt)
AT (1) ATE538810T1 (pt)
AU (1) AU2004268510B2 (pt)
BR (1) BRPI0412519A (pt)
CA (1) CA2532335C (pt)
DK (2) DK1644037T3 (pt)
ES (2) ES2380021T3 (pt)
HK (1) HK1091118A1 (pt)
IL (1) IL173071A (pt)
MX (1) MXPA06000469A (pt)
NZ (1) NZ544580A (pt)
PL (2) PL1644037T3 (pt)
PT (2) PT2343084E (pt)
RU (1) RU2369405C2 (pt)
SG (2) SG165378A1 (pt)
WO (1) WO2005020889A2 (pt)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
NZ553055A (en) * 2004-08-19 2008-12-24 Univ Cardiff Preparation of antigen-presenting human gamma delta T cells and use in immunotherapy
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
AU2006214278C1 (en) * 2005-02-16 2012-07-19 Miltenyi Biotec Technology, Inc. Lentiviral vectors and their use
CA2606429A1 (en) 2005-04-21 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
CN101325966B (zh) * 2005-10-18 2014-04-09 诺瓦瓦克斯股份有限公司 功能性流感病毒样颗粒(vlp)
CA2626489C (en) 2005-10-19 2020-10-27 University Of Florida Research Foundation, Inc Materials and methods for respiratory disease control in canines
US20070092871A1 (en) * 2005-10-20 2007-04-26 Combimatrix Corporation Microarray for pathogen identification
GB2432419A (en) * 2005-11-16 2007-05-23 Agency Science Tech & Res Influenza A virus detection method
FI20051255A0 (fi) * 2005-12-05 2005-12-05 Pekka Untamo Heino Seuraavaa influenssa A-pandemiaa vastaan soveltuva rokote
US8232058B2 (en) * 2006-01-20 2012-07-31 Lawrence Livermore National Security, Llc Multiplex detection of respiratory pathogens
AU2007212076B2 (en) * 2006-02-02 2012-10-18 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
WO2007126788A2 (en) * 2006-03-27 2007-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of viral infection
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP1998814A4 (en) * 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
KR100702034B1 (ko) * 2006-05-12 2007-03-30 삼성전자주식회사 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
AU2007297801A1 (en) 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US8097419B2 (en) * 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
WO2008100290A2 (en) 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
PL2601970T3 (pl) * 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
SI2540312T1 (sl) * 2007-07-19 2015-08-31 Novavax, Inc. Ptičji influenčni himerni VLP
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP2190471A4 (en) 2007-09-18 2012-05-09 Ligocyte Pharmaceuticals Inc METHOD FOR TRANSFERRING A PROTECTIVE REACTION ON NOROVIRES
ES2552858T3 (es) 2007-10-01 2015-12-02 Longhorn Vaccines And Diagnostics, Llc Recogida de muestras biológicas y sistema de transporte y métodos de uso
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2610345B1 (en) 2007-11-27 2015-08-19 Medicago Inc. Recombinant influenza virus-like particles (VLPS) produced in transgenic plants expressing hemagglutinin
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
WO2009102229A1 (ru) * 2008-02-15 2009-08-20 A.N. Belozersky Institute Of Physico-Chemical Biology, Moscow State University Липид-протеиновый рафтовый комплекс из оболочки вируса гриппа а для противогриппозных вакцин и способ его выделения, способ получения вирусоподобных частиц из таких комплексов
CN110075113A (zh) 2008-04-17 2019-08-02 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
WO2009128951A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of respiratory synctial virus proteins and methods of use
US8450056B2 (en) 2008-05-02 2013-05-28 University Of Rochester Arrayed imaging reflectometry (AIR) sensor chip comprising virus-like particles suitable for the detection of antiviral immune responses
CN102084252B (zh) * 2008-05-02 2017-03-22 罗切斯特大学 用于流感免疫应答测量的阵列检测器系统
CN101293099B (zh) * 2008-06-04 2010-12-08 厦门大学 一种抗多种亚型禽流感病毒的多肽疫苗及其制备方法
JP5809054B2 (ja) 2008-07-08 2015-11-10 メディカゴ インコーポレイテッド 可溶性組換えインフルエンザ抗原
JP5813505B2 (ja) * 2008-07-18 2015-11-17 メディカゴ インコーポレイテッド 新規インフルエンザウイルス免疫エピトープ
CA2742288A1 (en) * 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
IT1394782B1 (it) 2009-03-03 2012-07-13 Alenia Aeronautica Spa Procedimento di predizione di collisioni tra un velivolo e un aeromobile
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
EP2424980A1 (en) * 2009-05-01 2012-03-07 Redbiotec AG Recombinant virus-like particles encoded by multi-gene vector
CA2800182A1 (en) * 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
PL2445928T3 (pl) 2009-06-24 2018-07-31 Medicago Inc Chimeryczne, podobne do wirusa grypy cząsteczki zawierające hemaglutyninę
CA2766899C (en) 2009-07-02 2021-05-04 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
NZ598481A (en) 2009-09-22 2014-02-28 Medicago Inc Method of preparing plant-derived vlps
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
CA2789945A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
EP2544718A1 (en) 2010-03-11 2013-01-16 Immune Design Corp. Vaccines for pandemic influenza
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN102373182A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性囊病混合病毒样颗粒、制备方法和应用
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
EP2624864B1 (en) 2010-10-04 2017-12-06 Massachusetts Institute of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
ES2636965T3 (es) * 2010-11-05 2017-10-10 Novavax, Inc. Partículas tipo virus de la glicoproteína de la rabia (VLPs)
MX2013007255A (es) * 2010-12-22 2013-09-26 Novavax Inc Proteínas de hemaglutinina de influenza modificadas y sus usos.
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
ES2656527T3 (es) 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Formulaciones parenterales de vacunas de norovirus
CN103945863A (zh) 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
WO2013019800A1 (en) 2011-08-01 2013-02-07 Emory University Vlps containing ligands and methods related thereto
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2849434A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
SG10201604896TA (en) 2011-12-16 2016-08-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
CA2863083C (en) 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
IN2014DN05805A (pt) 2012-02-07 2015-05-15 Univ Pittsburgh
CN107188934A (zh) 2012-02-13 2017-09-22 高等教育联邦系统-匹兹堡大学 以计算方式优化的人和禽h5n1流感的广泛反应性抗原
RU2485973C1 (ru) * 2012-02-28 2013-06-27 Общество с ограниченной ответственностью "НТфарма" Рекомбинантная трехвалентная вакцина от гриппа человека
US9364530B2 (en) 2012-03-22 2016-06-14 Fraunhofer Usa, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
MX345150B (es) 2012-03-30 2017-01-18 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
WO2013177294A1 (en) * 2012-05-22 2013-11-28 Cornell University Reagents and methods for identifying anti-hiv compounds
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CA2885741C (en) 2012-09-21 2023-10-17 Frank Bedu-Addo Vaccine comprising r-dotap
KR101484588B1 (ko) 2012-10-24 2015-01-20 대한민국 개 인플루엔자 ｖｌｐ 백신의 제조방법
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
SG11201503989PA (en) 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105555301B (zh) 2013-08-13 2021-04-16 西北大学 肽缀合颗粒
CN103467581B (zh) * 2013-08-26 2016-01-20 中国科学院微生物研究所 流感病毒m1蛋白及其编码基因和应用
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
TWI714522B (zh) 2014-01-10 2021-01-01 加拿大商苜蓿股份有限公司 Cpmv強化子元件
HUE057800T2 (hu) 2014-04-23 2022-06-28 Modernatx Inc Nukleinsav vakcinák
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016010081A1 (ja) * 2014-07-18 2016-01-21 一般財団法人化学及血清療法研究所 ウイルス様粒子を含むワクチン
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
KR101745472B1 (ko) 2015-04-15 2017-06-12 대한민국 조류인플루엔자 바이러스의 세포 감염을 저해하는 물질을 선별하는 방법
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
JP2018530314A (ja) * 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
US10391163B2 (en) * 2015-09-10 2019-08-27 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CN107353328A (zh) * 2017-08-23 2017-11-17 上海市动物疫病预防控制中心 一种重组的h9n2亚型禽流感病毒样颗粒及其制备方法和用途
CN107488216B (zh) * 2017-09-06 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒通用疫苗及其制备方法与应用
CN110240634B (zh) * 2018-03-08 2022-09-06 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN110575538B (zh) * 2018-06-11 2022-08-19 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
JP2022522112A (ja) 2019-02-08 2022-04-14 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
CN113461786B (zh) * 2020-03-30 2022-09-13 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995022989A1 (en) 1994-02-24 1995-08-31 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
WO1996010633A1 (en) 1994-09-30 1996-04-11 Aviron Chimeric influenza virus and electroporation method
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5945489A (en) 1997-09-19 1999-08-31 Ashland, Inc. Liquid oligomers containing unsaturation
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US6513184B1 (en) 2000-06-28 2003-02-04 S. C. Johnson & Son, Inc. Particle entrapment system
CA2468957C (en) * 2001-12-07 2011-07-12 Crucell Holland B.V. Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
WO2003051835A2 (en) 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS

Also Published As

Publication number Publication date
PL2343084T3 (pl) 2013-09-30
CN1849134A (zh) 2006-10-18
US7763450B2 (en) 2010-07-27
NZ544580A (en) 2009-04-30
EP1644037B1 (en) 2011-12-28
PL1644037T3 (pl) 2012-05-31
US8592197B2 (en) 2013-11-26
US9474799B2 (en) 2016-10-25
CN103157103A (zh) 2013-06-19
EP2343084A1 (en) 2011-07-13
SG165378A1 (en) 2010-10-28
US20170232095A1 (en) 2017-08-17
ES2422580T3 (es) 2013-09-12
WO2005020889A2 (en) 2005-03-10
EP2343084B1 (en) 2013-04-24
MXPA06000469A (es) 2006-08-23
EP1644037A4 (en) 2008-04-23
IL173071A0 (en) 2006-06-11
AU2004268510A1 (en) 2005-03-10
KR20060052804A (ko) 2006-05-19
RU2006104113A (ru) 2006-07-27
CA2532335A1 (en) 2005-03-10
US20050009008A1 (en) 2005-01-13
ATE538810T1 (de) 2012-01-15
DK2343084T3 (da) 2013-07-22
PT1644037E (pt) 2012-04-10
US20130177587A1 (en) 2013-07-11
WO2005020889A3 (en) 2005-12-29
SG131116A1 (en) 2007-04-26
RU2369405C2 (ru) 2009-10-10
US20150306206A1 (en) 2015-10-29
CA2532335C (en) 2014-11-18
JP2015057447A (ja) 2015-03-26
US20060263804A1 (en) 2006-11-23
US9144607B2 (en) 2015-09-29
JP2013216685A (ja) 2013-10-24
CN107513102A (zh) 2017-12-26
US9956280B2 (en) 2018-05-01
JP2007529997A (ja) 2007-11-01
JP2011046715A (ja) 2011-03-10
ES2380021T3 (es) 2012-05-07
DK1644037T3 (da) 2012-04-10
JP2016164195A (ja) 2016-09-08
HK1091118A1 (en) 2007-01-12
PT2343084E (pt) 2013-07-18
KR101153929B1 (ko) 2012-07-05
EP1644037A2 (en) 2006-04-12
IL173071A (en) 2013-10-31
AU2004268510B2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
BRPI0412519A (pt) partìculas tipo vìrus da influenza funcional (vlps)
Jeong et al. Exploiting virus-like particles as innovative vaccines against emerging viral infections
ES2459166T3 (es) Procedimiento para la producción de vacunas víricas
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
TR201908199T4 (tr) HPV'ye karşı aşılar.
CY1113875T1 (el) Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
RU2008119501A (ru) Функциональные вирусоподоюные частицы гриппа (vlps)
Alexyuk et al. Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins
BRPI0707300A8 (pt) Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
ES2832733T3 (es) Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe
ATE552846T1 (de) Verbesserter grippeimpfstoff
BRPI0809842A8 (pt) processo para a obtenção de linhagens de células aviárias diploides contínuas, processo de replicação de um vírus em uma linhagem de células aviárias diploides contínuas e processo de produção de peptídeos e proteínas recombinantes
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
EP2708549A3 (en) Improved vaccines and methods for using the same
JP2022538693A (ja) タンパク質加水分解標的ウイルス、その生ワクチン及びその作製方法と用途
ECSP045300A (es) Antígenos virales
BR0312474A (pt) Partìcula viral adjuvante
Pushko et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus
ATE508185T1 (de) Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus
Bhatti et al. Nanoscale Interaction Mechanisms of Antiviral Activity
Chu et al. Respiratory viruses and virus-like particle vaccine development: how far have we advanced?
Cobbin et al. Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
Gencoglu Purification and effectiveness of vaccines and antiviral compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]